R.M. SHAKIROVA¹, G.M. KAMALOV¹, I.I. GALYAUTDINOVA², L.I. URAZAEVA²

¹Kazan State Mеdical University, Kazan

²Kazan (Volga Region) Federal University, Kazan

Contact details:

Shakirova R.M. — PhD (Medicine), Assistant Lecturer of the Department of Сardiology

Address: 49 Butlerov St., 420012 Kazan, Russian Federation, tel.: +7-917-297-76-94, e-mail: reginash77@mail.ru

Multiple sclerosis is associated with a higher risk of cardiovascular diseases and their complications. Comorbidities increase the likelihood of exacerbations of multiple sclerosis and are directly associated with the frequency of hospitalizations. The clinical manifestations of myocarditis can be diverse. Myocarditis associated with multiple sclerosis often has an atypical clinic picture, making it difficult to diagnose the disease. A clinical case of acute myocarditis in multiple sclerosis is presented. The clinical manifestations of myocarditis were similar to those in acute myocardial infarction. Coronary angiography has great diagnostic value in differential diagnostics. The tactics of management and treatment of comorbid patients with multiple sclerosis should be discussed by a multidisciplinary team.

Key words: acute myocarditis, multiple sclerosis, cardiovascular diseases.

REFERENCES

1. Vasileiou E., Fitzgerald K. Multiple sclerosis pathogenesis and updates in targeted therapeutic approaches. Allergy Asthma Rep, 2023, vol. 23, pp. 481–496.
2. Christiansen C., Christensen S., Farkas D. et al. Risk of arterial cardiovascular diseases in patients with multiple sclerosis: a population-based cohort study. Neuroepidemiology, 2010, vol. 35 (4), pp. 267–274.
3. Yang F., Hu T., He K. et al. Multiple Sclerosis and the Risk of Cardiovascular Diseases: A Mendelian Randomization Study. Immunol, 2022, vol. 13, pp. 861–885.
4. Imrich R., Vlcek M., Penesova A. et al. Cardiac autonomic function in patients with early multiple sclerosis. Auton. Res, 2021, vol. 31, pp. 553–562.
5. Paiva I., Badolato-Corrêa J., Familiar-Macedo D. et al. Th17 cells in viral infections-friend or Foe? Cells, 2021, vol. 10 (5), p. 1159.
6. Tschöpe C., Ammirati E., Bozkurt B. et al. Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Rev. Cardiol, 2021, vol. 18, pp. 169–193.
7. Chun J., Giovannoni G., Hunter S. Sphingosine 1-phosphate receptor modulator therapy for multiple sclerosis: differential downstream receptor signalling and clinical profile effects. Drugs, 2021, vol. 81, pp. 207–231.
8. Scolding N., Ali H., Sheppard M. et al. Alemtuzumab and fatal myocarditis. Clin. Pract, 2021, vol. 11, pp. 46–47.
9. Zavarella M., Villatore A., Rocca M. et al. The heart-brain interplay in multiple sclerosis from pathophysiology to clinical practice: a narrative review. Cardiovasc. Dev. Dis, 2023, vol. 10 (4), p. 153.